ImmunoMet Therapeutics Inc. logo

ImmunoMet Therapeutics, Inc.

ImmunoMet Therapeutics is a development-stage biopharmaceutical company focused on the development and commercialization of novel oncology products that are aimed to improve the quality of life of cancer patients.

0
Management
0
Technology
0
Deals/Partnering
0
Research Pipeline
0
Funding
BioStartup's Score 0 / 50

KEY DETAILS

Websitehttps://immunomet.com
Disease Focus
STOCK CODENon Listed
Address
JLABS at Texas Medical Center 2450 Holcombe Blvd 77021
Houston
United States
Email
Contact Number
+1 919-616-1923

[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=” ” connections=”true” suffix=””]

As a leader in cancer metabolism and immunometabolism, ImmunoMet Therapeutics has primarily been developing novel chemical entities blocking critical metabolic events of cancer cells and immunosuppressive cells. Our product candidates are designed to combat cancers by preferentially targeting resistant cancer subpopulation and immunosuppressive cells primarily in combination with the current standard of care therapies. Our development platforms have the potential to treat a broad range of cancer types.

In Mar 2017, ImmunoMet raised $5 Mn in Series B round with participation from Intervest, SL Investment, NHN Investment along with the Series A investors Mirae Asset Venture Investments, GNTech and Dr. Sung-wuk Kim, founder of ImmunoMet.

In Mar 2016, ImmunoMet raised $5.2 Mn in a Series A financing led by Mirae Asset Venture Investments (Mirae Asset) with participation from Aju Tech, GNTech, and MetaVest.